129 related articles for article (PubMed ID: 34495724)
1. Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature Review.
Rand LZ; Kesselheim AS
Health Aff (Millwood); 2021 Sep; 40(9):1402-1410. PubMed ID: 34495724
[TBL] [Abstract][Full Text] [Related]
2. Alternatives to the quality-adjusted life year: How well do they address common criticisms?
Rand LZ; Melendez-Torres GJ; Kesselheim AS
Health Serv Res; 2023 Apr; 58(2):433-444. PubMed ID: 36537647
[TBL] [Abstract][Full Text] [Related]
3. Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets.
Chapman RH; Kumar VM; Whittington MD; Pearson SD
Value Health; 2021 Jun; 24(6):839-845. PubMed ID: 34119082
[TBL] [Abstract][Full Text] [Related]
4. [Controversies around QALYs].
Rogalewicz V; Barták M
Vnitr Lek; 2017; 63(4):242-248. PubMed ID: 28520447
[TBL] [Abstract][Full Text] [Related]
5. The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?
Sandmann FG; Mostardt S; Lhachimi SK; Gerber-Grote A
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):475-486. PubMed ID: 29979895
[TBL] [Abstract][Full Text] [Related]
6. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
7. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
Parmar A; Jiao T; Saluja R; Chan KKW
Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
9. Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies.
Nord E
Eur J Health Econ; 2018 Mar; 19(2):267-275. PubMed ID: 28258399
[TBL] [Abstract][Full Text] [Related]
10. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
[TBL] [Abstract][Full Text] [Related]
11. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
12. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
13. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value.
Sharma S; Bakal J; Sharma SM; Covert D; Shah GK
Can J Ophthalmol; 2005 Jun; 40(3):369-77. PubMed ID: 15947806
[TBL] [Abstract][Full Text] [Related]
14. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Beresniak A; Dupont D
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
[TBL] [Abstract][Full Text] [Related]
15. Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value.
Campbell JD; Belozeroff V; Whittington MD; Rubin RJ; Raggi P; Briggs AH
Health Aff (Millwood); 2018 Aug; 37(8):1298-1305. PubMed ID: 30080450
[TBL] [Abstract][Full Text] [Related]
16. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
[TBL] [Abstract][Full Text] [Related]
20. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(6):1-51. PubMed ID: 27110317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]